Sacral insufficiency fracture after pelvic radiotherapy: a diagnostic challenge for a radiologist.

Sacral insufficiency fractures can occur as a complication after pelvic radiotherapy. Despite several recent studies showing high incidence of sacral insufficiency fractures in elderly women after pelvic radiotherapy this condition still remains underdiagnosed. We present a case of sudden onset of low back pain in a female patient with a history of cervical cancer radiotherapy. Initial diagnostic imaging misinterpreted SIF for metastasis. Bone scan and single-photon emission-computed tomography with low-dose computed tomography revealed the correct diagnosis. Due to the reasons that sacral insufficiency fractures still remain underdiagnosed this report is important to practical routine work of oncologists and radiologists.

The 99mTc-MIP-1404 PSMA Uptake in the Isolated Paratracheal Lymph Node From the Prostate Adenocarcinoma.

ABSTRACT: The oncologist consulted a 56-year-old man after receiving prostate-specific antigen screening results. Prostate-specific antigen level during the screen time was 33 ng/mL. As a result, poorly differentiated prostate adenocarcinoma with a Gleason score of 9 (5 + 4) was diagnosed. SPECT/CT scan with 99mTc-MIP-1404 PSMA tracer was performed. The 99mTc-PSMA-positive lesions were detected in the prostate, external iliac, obturator lymph nodes of the pelvis, para-aortic, and the right lower paratracheal space. The patient was prescribed androgen deprivation therapy and early chemotherapy with docetaxel (6 fractions), after which radiation therapy to prostate and seminal vesicles was planned.

Diagnosing sacral insufficiency fractures after radiotherapy in women with cervical cancer: Report of three cases.

INTRODUCTION: Diagnosing sacral insufficiency fractures (SIF) in oncology patients is a challenge to radiologists, and recognition of imaging features is essential in order to avoid misdiagnosis of bone metastases and prevent patients from inaccurate treatment. CLINICAL CASES: in order to better understand the essence of this pathology and to make diagnosis easier, we present three clinical cases of SIF in patients with cervical cancer. All patients received radiation therapy (external beam radiation and brachytherapy) and chemotherapy with cisplatin. Patients underwent pelvic MRI, CT, SPECT or SPECT/CT examinations. One patient underwent a FDG-PET/CT examination. CONCLUSIONS: SPECT/CT should be included in the differential diagnostics when radiological features of pelvic bone pathology on CT or MRI are undetermined or SIF are suspected. SIF must always be considered in oncology patients with pelvic pain, especially in postmenopausal state and after radiation therapy. For patients with osteoporosis, bone density screening and precise review of the most common fracture sites are recommended.

The Impact of the COVID-19 Pandemic on Cancer Patient's Management-Lithuanian Cancer Center Experience.

The pandemic spread of the COVID-19 virus significantly affected daily life, but the highest pressure was piled on the health care system. Our aim was to evaluate an impact of COVID-19 pandemic management measures on cancer services at the National Cancer Institute (NCI) of Lithuania. We assessed the time period from 1 February 2020 to 31 December 2020 and compared it to the same period of 2019. Data for our analysis were extracted from the NCI Hospital Information System (HIS) and the National Health Insurance Fund (NHIF). Contingency table analysis and ANOVA were performed. The COVID-19 pandemic negatively affected the cancer services provided by NCI. Reductions in diagnostic radiology (-16%) and endoscopy (-29%) procedures were accompanied by a decreased number of patients with ongoing medical (-30%), radiation (-6%) or surgical (-10%) treatment. The changes in the number of newly diagnosed cancer patients were dependent on tumor type and disease stage, showing a rise in advanced disease at diagnosis already during the early period of the first lockdown. The extent of out-patient consultations (-14%) and disease follow-up visits (-16%) was also affected by the pandemic, and only referrals to psychological/psychiatric counselling were increased. Additionally, the COVID-19 pandemic had an impact on the structure of cancer services by fostering the application of modified systemic anticancer therapy or hypofractionated radiotherapy. The most dramatic drop occurred in the number of patients participating in cancer prevention programs; the loss was 25% for colon cancer and 62% for breast cancer screening. Marked restriction in access to preventive cancer screening and overall reduction of the whole spectrum of cancer services may negatively affect cancer survival measures in the nearest future.

[Outcomes of long-term combined treatment in follicular thyroid carcinoma]. / Folikulinio skydliaukes vezio ilgalaikio kompleksinio gydymo rezultatai.

UNLABELLED: The aim was to analyze the impact of combined treatment (thyroidectomy + radioactive iodine treatment + hormonotherapy with thyroxine) on the outcomes of patients with follicular thyroid carcinoma. MATERIAL AND METHODS: This retrospective study included 448 patients with follicular carcinoma (394 females, 54 males, mean age of 48 years (95% CI, 46-50 years) who were treated at the Institute of Oncology, Vilnius University, from 1982 to 2006. All the patients underwent thyroidectomy. Hypothyroid patients 3-12 weeks after surgical treatment were treated with moderate radioiodine doses (1.11-3.7 GBq), and these doses were administered every 3-4 months. The patients with follicular thyroid carcinoma were given suppressive doses of thyroxine after combined treatment. The patients treated were regularly observed by gamma camera; every 6-12 months, serum thyroglobulin was evaluated. RESULTS: The remnants of thyroid tissue were detected in all 448 patients after thyroidectomy and radioiodine therapy. Radioiodine at mean total doses of 5.6+/-0.2 GBq was used to destroy the remnants of thyroid tissue. For patients with disseminated forms of follicular thyroid carcinoma, mean total radioiodine doses of 19.5+/-3.1 GBq were used. Majority (91.2%) of the patients were euthyroid or hyperthyroid after the treatment with thyroid hormone. All the patients treated had the level of serum thyroglobulin of 1.1+/-0.2 ng/mL. The overall 10-, 20-, and 30-year survival of patients with follicular thyroid cancer, who received combined treatment, was 91.2%, 81.9%, and 77.1%, respectively. CONCLUSION: Combined treatment (thyroidectomy + radioactive iodine treatment + hormonotherapy with thyroxine) administered to the patients with follicular thyroid carcinoma is highly effective, because overall 10-, 20-, 30-year survival was 91.2%, 81.9%, 77.1%, respectively.